Pharmaceutical Companies(BK7508),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

BK7508 Pharmaceutical Companies

Trading 12-23 12:07:51 AEDT

655.05

-1.04

-0.16%

High658.39	Low653.63	Vol20.10M
Open654.91	D1 Closing656.08	Amplitude0.73%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O47.67M	T/O Rate--	Tradable Shares0.00
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":655.04736,"timestamp":1766452070176,"preClose":656.0824,"halted":0,"volume":20103117,"delay":0,"changeRate":-0.001578,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-1.035034,"latestTime":"12-23 12:07:51 AEDT","open":654.909,"high":658.3928,"low":653.63226,"amount":47674199,"amplitude":0.007256,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766466000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1766444400000,1766466000000]],"turnoverRate":0.000772,"increases":15,"decrements":12,"flats":17,"marketCap":98088781108.75,"floatMarketCap":94625408571.5625},"requestUrl":"/m/hq/s/BK7508/wiki","defaultTab":"wiki","newsList":[{"id":"2593545170","title":"BUZZ-Australia's Immutep hits 15-month high on positive IMP761 trial update","url":"https://stock-news.laohu8.com/highlight/detail?id=2593545170","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593545170?lang=en_us&edition=fundamental","pubTime":"2025-12-23 08:44","pubTimestamp":1766450664,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Immutep hits 15-month high on positive IMP761 trial update** Shares of Australia's Immutep IMM.AX rise as much as 3.8% to A$0.415, their highest since September 13, 2024** Biotech fir","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nL6N3XT00R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2593845604","title":"Biotron Ltd-Director Appointment DR Paul Kasian & Appendix 3X","url":"https://stock-news.laohu8.com/highlight/detail?id=2593845604","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593845604?lang=en_us&edition=fundamental","pubTime":"2025-12-23 07:40","pubTimestamp":1766446821,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUE32P6DQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIT.AU","BK7501","BK7508","BK7067"],"gpt_icon":0},{"id":"2593456501","title":"Paradigm Biopharmaceuticals Moves to Reach Patient Recruitment Milestone in Phase 3 Knee Osteoarthritis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2593456501","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593456501?lang=en_us&edition=fundamental","pubTime":"2025-12-23 07:10","pubTimestamp":1766445036,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  said it has the required number of participants to meet the 25% recruitment milestone for its phase 3 PARA_OA_012 clinical trial, according to a Tuesday filing with the Australian bourse.The trial is evaluating the company's drug candidate, injectable pentosan polysulfate sodium, for the potential treatment of knee osteoarthritis, the filing said.The company expects to start dosing a number of participants in the trial next year, and sees the 50% recruitment milestone achieved shortly after the completion of the 25% dosing milestone, the filing added.The company said it is on track for an interim analysis of the trial in mid-2026. The primary endpoint analysis for the full patient group is expected in the fourth quarter of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","PAR.AU","BK7508"],"gpt_icon":0},{"id":"2593551544","title":"Invion Ltd -  Work Program Estimated to Be Worth up to a$2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2593551544","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593551544?lang=en_us&edition=fundamental","pubTime":"2025-12-23 06:38","pubTimestamp":1766443118,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nFWN3XS0AN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7509","BK7096","IVX.AU","BK7508"],"gpt_icon":0},{"id":"2593455159","title":"Invion Ltd - Non-Dilutive Funding Secured From Hanlim Pharm and Korean Govt Research Fund for Esophageal Cancer Preclinical Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2593455159","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593455159?lang=en_us&edition=fundamental","pubTime":"2025-12-23 06:38","pubTimestamp":1766443118,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nFWN3XS0AN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IVX.AU","BK7508","BK7096","BK7509"],"gpt_icon":0},{"id":"2593453935","title":"Opthea Limited Issues New Options to Directors Under NED Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2593453935","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593453935?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:50","pubTimestamp":1766440238,"startTime":"0","endTime":"0","summary":"Opthea Limited has issued 41,000,000 unquoted options to acquire fully paid ordinary shares to director Ms Katherine Connell. These options, expiring 11 November 2035, were granted under the Non-Executive Directors Share and Option Plan, as approved at the Annual General Meeting on 11 November 2025. No consideration was paid for the options.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opthea Limited published the original content used to generate this news brief on December 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL7bB3lC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPT.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2593436422","title":"Asian Equities Traded in the US as American Depositary Receipts Rise in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2593436422","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593436422?lang=en_us&edition=fundamental","pubTime":"2025-12-22 23:33","pubTimestamp":1766417606,"startTime":"0","endTime":"0","summary":"Asian equities traded in the US as American depositary receipts opened the week higher Monday morning, rising 0.38% to 2,687.28 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by used car platform Uxin  and education company 17 Education & Technology Group , which climbed 13% and 12%, respectively. They were followed by computer hardware maker Canaan  and fintech firm Qfin , which advanced 4.9% and 4.1%, respectively.The decliners from North Asia were led by automotive marketplace Token Cat  and lender CNFinance , which fell  5.3% and 4.8%, respectively. They were followed by  game live-streaming service HUYA  and online game developer The9 , which were down 3% and 2.8%, respectively.From South Asia, the gainers were led by IT firm Sify Technologies  and telecommunications operator PLDT , which rose  5.1% and 1.2%, respectively. They were followed by lender HDFC Bank  and tech conglomerate Sea , which were up 0.6% and 0.5%, respectively.The decliners from South Asia ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LU2087589342.USD","BK4551","BK4533","BK4600","LU0633140727.USD","BK7016","BK4195","LU0737861269.HKD","LU0918141887.USD","LU0708995666.HKD","LU1366334578.USD","SG9999014484.SGD","SG9999002406.SGD","LU1805238398.USD","HUYA","LU1242518857.USD","LU1854104046.USD","BK7508","IE0031814969.USD","IE00B0JY6M65.USD","LU0630378692.HKD","LU0528227936.USD","LU0683595622.HKD","SG9999013486.USD","SG9999014492.USD","LU0918141705.HKD","LU0345775950.USD","03660","SG9999002620.SGD","BK4513","LU0541501648.USD","LU0175139822.USD","BK4595","LU0516422952.EUR","LU0456842615.SGD","SG9999014005.SGD","WIT","LU0862451753.SGD","LU2476274720.SGD","BK4220","LU1282648689.USD","LU1323998911.USD","LU0345776255.USD","LU1267930656.SGD","LU1242518931.SGD","LU0264606111.USD","LU0164881194.USD","SG9999002604.SGD","LU0868486357.SGD","LU0287143357.SGD","IE00BYTNYM70.SGD","UXIN","LU0197773673.USD","LU0979878070.USD","SG9999001135.SGD","TC","LU1791710582.SGD","BK4503","NCTY","SG9999002414.USD","LU2238330802.EUR","BK4207","LU0348744763.USD","IE0001KFT4U8.USD","LU0516423174.USD","LU2065171311.SGD","LU0791590937.USD","BK4577","LU1808992512.USD","BK4023","SG9999014013.SGD","SG9999005177.SGD","LU0831103253.SGD","IE00B7N09G41.SGD","LU0289960550.SGD","LU0630378429.USD","LU1508157978.USD","BK4526","BK4117","LU1854103824.USD","LU2279701549.SGD","LU0261945553.USD","LU0516423091.SGD","LU1981816686.USD","BK4557","SG9999004360.SGD","LU1102505762.USD","LU2177674079.SGD","IE0034224299.USD","BK4566","LU0307460401.USD","LU0791591158.USD","BK4132","BK4115","BK4134","IE00BD6J9T35.USD","LU1770036033.HKD","LU2008162690.USD","LU0572940350.SGD","LU1861220207.SGD","LU0390134368.USD","RDY","BK4505","LU0633140560.USD","BK4523","BK4509","LU2125910849.SGD","BK7096","BK4554","LU1839390173.USD","LU0532188223.SGD","LU2152927971.USD","LU2065171402.SGD","LU0197229882.USD","CNF","LU0898667661.SGD","SG9999014021.USD","LU0541502299.USD","BK4214","BK4085","LU0333810181.USD","TLK","LU0572939691.SGD","LU1048588211.SGD","BK4563","LU0348788117.USD","BK4588","LU2226246903.HKD","LU0231203729.USD","YQ","LU0531971678.HKD","SG9999014039.USD","LU0048573645.USD","BK4548","LU1105468828.SGD","SIFY","BK4122","BK4532","BK4581","LU0823038988.USD","BK4089","SG9999013460.SGD","LU0441851309.USD","SG9999006266.SGD","BK4596","LU1791710400.SGD","LU2125910500.SGD","LU0348816934.USD","SG9999002679.SGD","BK4170","IE00B3M56506.USD","BK4535","LU2065169927.USD","BK4585","INFY","LU0431992006.USD","LU2476274308.USD","BK4204","LU0536402901.SGD","LU0797268264.HKD","LU2543165471.USD","LU0499858602.USD","BK4531","LU0499858438.USD","LU1366334651.USD","BK4009","LU2045819591.USD","QFIN","LU2663582299.SGD","LU2065170008.USD","PHI","BK7502","LU0210637038.USD","LU2360107671.USD","LU0589944569.HKD","LU0072462343.USD","LU0516422440.USD","LU1861217088.USD","LU0197773160.USD","LU1804176565.USD","LU2778985437.USD","SGXZ58947870.SGD","BK4229","BK4510","LU0348814723.USD","HDB","LU0066902890.USD","LU0516422366.SGD","LU0823039010.USD","SG9999013478.USD","BK4107","LU0251143029.SGD","LU0890818403.SGD","LU2265009873.SGD","CAN","BK4166"],"gpt_icon":1},{"id":"2593487707","title":"Immutep Announces Positive Update on Imp761, a First-in-Class Lag-3 Agonist Antibody for Autoimmune Diseases, From Phase I Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2593487707","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593487707?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:00","pubTimestamp":1766408403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA9D6J4H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2593487092","title":"Immutep Ltd - Trial to Continue With Updates Expected in 1H Cy2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2593487092","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593487092?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:00","pubTimestamp":1766408403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA9D6J4H:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2593487002","title":"Immutep Ltd - Dose Dependent Immunosuppressive Effect Observed With Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2593487002","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593487002?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:00","pubTimestamp":1766408403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA9D6J4H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"2593031731","title":"BUZZ-Australia's Dimerix hits 7-month high on $4.8 billion sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2593031731","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593031731?lang=en_us&edition=fundamental","pubTime":"2025-12-22 12:10","pubTimestamp":1766376612,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Dimerix hits 7-month high on $4.8 billion sale** Shares of Dimerix DXB.AX rise as much as 12.5% to A$0.63, its highest level in seven months** Stock touches its biggest intraday pct gain in six months, if gains hold** Biotech co says U.S. listed biotech firm, BioMarin Pharmaceutical BMRN.O to acquire co's U.S. commercial licensing partner, Amicus Therapeutics for $4.8 billion** Amicus Therapeutics is a biopharma co, licensing DXB's drug, DMX-200, for U.S. market to treat rare kidney diseases** Stock up 80.89% YTD, including session's moves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nL6N3XS07Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IE00B19Z3B42.SGD","BK7501","BMRN","FOLD","BK7508","IE0002270589.USD","BK4139","LU2065170008.USD","IE00B19Z3581.USD","LU2065169927.USD","IE00B7SZLL34.SGD","DXB.AU","LU2065171402.SGD","LU2065171311.SGD","BK7067"],"gpt_icon":0},{"id":"2593177775","title":"Mayne Pharma Group Says Net Revenues Fall 5.5% Year on Year  for the Period Between July, November","url":"https://stock-news.laohu8.com/highlight/detail?id=2593177775","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593177775?lang=en_us&edition=fundamental","pubTime":"2025-12-22 10:35","pubTimestamp":1766370944,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group  said that during the period from July to November, its net revenues were AU$165 million, falling 5.5% from the same period in the previous year, according to a Monday Australian bourse filing.The Women's Health sector was flat at $50.8 million while dermatology was down 12% to $37.1 million over the same period. The Women's Health sector saw continued growth with demand for total prescriptions showing continued volume growth through the first five months of fiscal year 2026.Underlying earnings before interest, taxes, depreciation, and amortization for the period was AU$11.5 million compared to the prior-year EBITDA of AU$22.4 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2593171444","title":"BRIEF-Neuren Pharmaceuticals Says Health Canada Approves Clinical Trial Application For NNZ-2591","url":"https://stock-news.laohu8.com/highlight/detail?id=2593171444","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593171444?lang=en_us&edition=fundamental","pubTime":"2025-12-22 08:58","pubTimestamp":1766365097,"startTime":"0","endTime":"0","summary":"BRIEF-Neuren Pharmaceuticals Says Health Canada Approves Clinical Trial Application For NNZ-2591Dec 22 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX:HEALTH CANADA APPROVES CLINICAL TRIAL APPLICATION FOR NNZ-2591Further company coverage: NEU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nFWN3XQ039:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","NEU.AU"],"gpt_icon":0},{"id":"2593171449","title":"BRIEF-Mayne Pharma Says Net Revenues Were A$165 Million For First 5 Months Of FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2593171449","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593171449?lang=en_us&edition=fundamental","pubTime":"2025-12-22 08:58","pubTimestamp":1766365085,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma Says Net Revenues Were A$165 Million For First 5 Months Of FY26Dec 22  - Mayne Pharma Group Ltd MYX.AX:UNDERLYING EBITDA FOR FIRST 5 MONTHS OF FY26 WAS A$11.5MNET REVENUES WERE A$165 MILLION FOR FIRST 5 MONTHS OF FY26Further company coverage: MYX.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nFWN3XR02U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2593711881","title":"Immutep Completes Two Dosing Levels in Single-Ascending Dose Portion of Phase 1 Autoimmune Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2593711881","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593711881?lang=en_us&edition=fundamental","pubTime":"2025-12-22 08:48","pubTimestamp":1766364498,"startTime":"0","endTime":"0","summary":"Immutep  said the single-ascending dose portion of its first-in-human phase one study evaluating its IMP761 treatment candidate, an antibody for autoimmune diseases, completed the 2.5-milligram-per-kilogram and 7-milligram-per-kilogram dosing levels in healthy participants, according to a Monday Australian bourse filing.IMP761 was tolerated well with no treatment-related adverse reactions beyond mild intensity, per the filing. Evidence of dose-dependent immunosuppressive effects was observed with \"significant,\" long-lasting inhibition of the three T-cell mediated intradermal reactions to a strong foreign antigen at days two, nine, and 23.The firm's shares fell past 1% in recent trading on Monday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2593762001","title":"BUZZ-Australia's Neuren Pharma climbs after Canada approves drug trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2593762001","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593762001?lang=en_us&edition=fundamental","pubTime":"2025-12-22 07:28","pubTimestamp":1766359706,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren Pharma climbs after Canada approves drug trial** Shares of Australia's Neuren Pharmaceuticals NEU.AX rise as much as 2.8% to A$20.13** Biopharma firm announces Health Canada ha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251221:nL6N3XR07S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2593176949","title":"Dimerix Agrees to Acquire US Licensing Partner for Nearly $5 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2593176949","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593176949?lang=en_us&edition=fundamental","pubTime":"2025-12-22 07:05","pubTimestamp":1766358347,"startTime":"0","endTime":"0","summary":"Dimerix  agreed to acquire its US commercial licensing partner, Amicus Therapeutics, for about $4.8 billion in cash, according to a Friday filing with the Australian bourse.The deal includes the company's commercial licensing contract, under which the company is eligible to receive $590 million in payments, the filing said.The company's license deals outside the US remain unaffected, the filing added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7508","BK7501","BK7067"],"gpt_icon":0},{"id":"2593176314","title":"Neuren Pharmaceuticals Ltd -  Health Canada Approves Clinical Trial Application for Nnz-2591","url":"https://stock-news.laohu8.com/highlight/detail?id=2593176314","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593176314?lang=en_us&edition=fundamental","pubTime":"2025-12-22 06:49","pubTimestamp":1766357354,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251221:nFWN3XQ039:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","NEU.AU","BK7096"],"gpt_icon":0},{"id":"2593175233","title":"Dimerix Ltd-Biomarin to Acquire Dimerix US Partner, Amicus Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2593175233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593175233?lang=en_us&edition=fundamental","pubTime":"2025-12-22 06:16","pubTimestamp":1766355415,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251221:nTUEBNHV0W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7508","BK7067","DXB.AU"],"gpt_icon":0},{"id":"2593756291","title":"Mayne Pharma Group -  Net Revenues Were a$165 Mln for First 5 Months of FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2593756291","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593756291?lang=en_us&edition=fundamental","pubTime":"2025-12-22 05:44","pubTimestamp":1766353491,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251221:nFWN3XR02U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7096","BK7508"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0271},{"period":"1month","weight":0.0456},{"period":"3month","weight":0.0595},{"period":"6month","weight":0.0983},{"period":"1year","weight":0.2726},{"period":"ytd","weight":0.2594}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"name":"BK7508","nameEN":"BK7508"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pharmaceutical Companies(BK7508),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pharmaceutical Companies(BK7508) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pharmaceutical Companies,BK7508,Pharmaceutical Companies股票,Pharmaceutical Companies股票老虎,Pharmaceutical Companies股票老虎国际,Pharmaceutical Companies行情,Pharmaceutical Companies股票行情,Pharmaceutical Companies股价,Pharmaceutical Companies股市,Pharmaceutical Companies股票价格,Pharmaceutical Companies股票交易,Pharmaceutical Companies股票购买,Pharmaceutical Companies股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pharmaceutical Companies(BK7508),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pharmaceutical Companies(BK7508) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction